The ability to detect and quantify tau pathology in vivo using these tracers can aid in the early diagnosis of AD and other tauopathies and provide a way to monitor disease progression and determine the effectiveness of therapeutic interventions [7]. The gene discussed is MAPT; the disease is Alzheimer disease.